Thelin Gets EMEA Committee Approval Recommendation
This article was originally published in The Pink Sheet Daily
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing authorization approval of Encysive's pulmonary arterial hypertension therapy Thelin (sitaxsentan), the agency announced June 2
You may also be interested in...
Encysive’s Thelin Gets EU Nod Ahead Of U.S.
EU marketing authorization of the pulmonary arterial hypertension treatment follows Encysive’s receipt of a second “approvable” letter for sitaxentan sodium from FDA.
Encysive’s Thelin Gets EU Nod Ahead Of U.S.
EU marketing authorization of the pulmonary arterial hypertension treatment follows Encysive’s receipt of a second “approvable” letter for sitaxentan sodium from FDA.
TopoTarget’s Dexrazoxane Approved In EU, “Approvable” In U.S.
Company may seek partner to market drug in the U.S. after addressing manufacturing issues.